Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New anticoagulants: current status and future potential.

Jeffrey I Weitz1, Mark A Crowther

  • 1Department of Medicine, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada. jweitz@thrombosis.hhscr.org

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|January 20, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aspirin Dosing Frequency and Dose Influence Thromboxane Suppression Despite Uniform Inhibition of Arachidonic Acid-induced Platelet Aggregation.

TH open : companion journal to thrombosis and haemostasis·2026
Same author

Poly(sulfobetaine-<i>co</i>-oligoethylene Glycol Methyl Ether Methacrylate) Copolymers with Improved Anti-Fouling and Anti-Coagulant Properties.

Biomacromolecules·2026
Same author

A novel biosensor for measuring plasmin activity.

Research and practice in thrombosis and haemostasis·2026
Same author

Prior anticoagulation experience and bleeding risk with the factor XI inhibitor abelacimab in AZALEA-TIMI 71.

Blood·2026
Same author

Long-Term Hydrophilic, Anti-Clotting, and Anti-Fibrotic Dynamic Covalent Silicone-Based Biomaterials.

Advanced healthcare materials·2026
Same author

Pharmacologic Factor XI/XIa Inhibitors: What the Laboratory Hematologist Needs to Know.

Clinics in laboratory medicine·2026

New anticoagulants offer improved treatments for arterial and venous thrombosis, overcoming limitations of traditional drugs like heparin and warfarin. These novel agents target various stages of the coagulation cascade for better patient outcomes.

Area of Science:

  • Pharmacology
  • Hematology
  • Drug Development

Background:

  • Arterial and venous thrombosis contribute significantly to morbidity and mortality.
  • Current anticoagulants, heparin and warfarin, possess limitations hindering clinical use.
  • Significant healthcare costs are associated with thrombosis treatment and complications.

Purpose of the Study:

  • To review new anticoagulant drugs in advanced clinical evaluation.
  • To discuss novel agents designed to overcome existing anticoagulant limitations.
  • To highlight advancements in targeting the coagulation cascade for thrombosis treatment.

Main Methods:

  • Review of scientific literature on novel anticoagulant drug development.
  • Focus on drugs targeting specific factors in the coagulation cascade.

Related Experiment Videos

  • Categorization of anticoagulants based on their targeted step in coagulation.

    • Main Results:

    • Development of new anticoagulants targeting coagulation initiation (e.g., TFPI, anti-factor VIIa).
    • Emergence of inhibitors targeting coagulation propagation (e.g., anti-factor IXa, factor Xa inhibitors, fondaparinux).
    • Availability of novel thrombin inhibitors (e.g., hirudin, bivalirudin, argatroban, ximelagatran).

    Conclusions:

    • New anticoagulants offer diverse strategies to inhibit thrombosis.
    • These agents target various enzymatic steps within the coagulation pathway.
    • Advanced clinical evaluation suggests potential improvements over existing therapies.